Drug resistance pattern of <i>M. tuberculosis</i> in those who developed the disease after exposure to MDR/XDR pulmonary tuberculosis

Drug resistance pattern of <i>M. tuberculosis</i> in those who developed the disease after exposure to MDR/XDR pulmonary tuberculosis

.

Bibliographic Details
Main Authors:	K. A. Glebov, V. A. Guseva, I. A. Burmistrova, O. V. Lovacheva, A. G. Samoylova, I. A. Vasilyeva
Format:	Article
Language:	Russian
Published:	New Terra Publishing House 2020-01-01
Series:	Туберкулез и болезни лёгких
Online Access:	https://www.tibl-journal.com/jour/article/view/1372

Similar Items

INDIVIDUAL TREATMENT OF PULMONARY MDR/XDR TUBERCULOSIS IN ADOLESCENTS
by: L. V. Pаnovа, et al.
Published: (2018-03-01)

Amplification of drug resistance against the background of inadequate chemotherapy for pulmonary tuberculosis
by: I. A. Burmistrova, et al.
Published: (2019-09-01)

RELATIONSHIP BETWEEN DETECTION OF TB AND TREATMENT OF MDR/XDR TB
by: V. Guseva, et al.
Published: (2023-08-01)

The multivariate analysis of results of bedaquiline use in the therapy of MDR/XDR pulmonary tuberculosis
by: N. V. Stavitskaya, et al.
Published: (2020-08-01)

Transmission of MDR and XDR tuberculosis in Shanghai, China.
by: Ming Zhao, et al.
Published: (2009-01-01)

Activity of Semi-Synthetic Mulinanes against MDR, Pre-XDR, and XDR Strains of <i>Mycobacterium tuberculosis</i>
by: María Alejandrina Martínez-González, et al.
Published: (2021-12-01)

Cost-effectiveness of bedaquiline in MDR and XDR tuberculosis in Italy
by: Luigi R. Codecasa, et al.
Published: (2017-01-01)

Results of treatment with bedaquiline containing regimens of MDR/XDR tuberculosis patients including those with concurrent HIV infection (the experience of Leningrad Region)
by: T. I. Danilova, et al.
Published: (2020-10-01)

The rationale for using rifabutin in the treatment of MDR and XDR tuberculosis outbreaks.
by: Frederick A Sirgel, et al.
Published: (2013-01-01)

Comparative analysis of eﬃcacy and safety of various anti-tuberculosis therapy regimens in patients with MDR/XDR tuberculosis
by: E. P. Myshkova, et al.
Published: (2022-06-01)

RANGES OF DRUG RESISTANCE OF THE PATHOGEN SENSITIVE TO RIFAMPICIN AND RESISTANT TO ISONIAZID IN PULMONARY TUBERCULOSIS PATIENTS
by: I. A. Burmistrova, et al.
Published: (2019-01-01)

Safety of chemotherapy of MDR/XDR-TB patients in high HIV prevalence settings
by: A. V. Kukurika, et al.
Published: (2022-12-01)

MDR and Pre-XDR Clinical <i>Mycobacterium tuberculosis</i> Beijing Strains: Assessment of Virulence and Host Cytokine Response in Mice Infectious Model
by: Mikhail V. Fursov, et al.
Published: (2021-08-01)

The burden of MDR/XDR tuberculosis in coastal plains population of China.
by: Xiujun Yang, et al.
Published: (2015-01-01)

Correction: The Rationale for Using Rifabutin in the Treatment of MDR and XDR Tuberculosis Outbreaks.
by: Frederick A Sirgel, et al.
Published: (2015-01-01)

The effect of the current chemotherapy of MDR/XDR tuberculosis on QT interval changes in ECG
by: E. M. Zhukova, et al.
Published: (2019-12-01)

Linezolid-Associated Neuropathy in Patients with MDR/XDR Tuberculosis in Shenzhen, China
by: Zhang P, et al.
Published: (2022-05-01)

Epidemiologic characteristics of MDR/XDR tuberculosis in Montenegro, from 2005 to 2018
by: O. Bojovic, et al.
Published: (2020-12-01)

Experience of using a combination mucoactive drug during chemotherapy in patients with MDR/XDR tuberculosis
by: E. P. Myshkova, et al.
Published: (2020-08-01)

Specific Parameters of Detection of Fungi of the Genus <i>Aspergillus</i> in Respiratory Organs of Pulmonary Tuberculosis Patients
by: A. E. Panova, et al.
Published: (2023-01-01)

Drug resistance of <i>M. tuberculosis</i> (historical aspects, current level of knowledge)
by: I. A. Burmistrova, et al.
Published: (2020-02-01)

ECONOMIC FEASIBILITY OF NEW CHEMOTHERAPY REGIMENS FOR TREATMENT OF TUBERCULOSIS PATIENTS WITH EXTENSIVE DRUG RESISTANCE
by: I. A. Vasilyeva, et al.
Published: (2018-07-01)

MDR/XDR-TB Colour Test for drug susceptibility testing of Mycobacterium tuberculosis, Northwest Ethiopia
by: Agumas Shibabaw, et al.
Published: (2020-01-01)

Tratamiento de tuberculosis MDR / XDR en Perú. ¿Vamos por buen camino?
by: Samuel Pecho-Silva
Published: (2020-06-01)

Association of anti-tuberculosis drug concentrations in hair and treatment outcomes in MDR- and XDR-TB
by: John Metcalfe, et al.
Published: (2019-04-01)

Short course treatment of pulmonary tuberculosis patients suffering from multiple drug resistance. The current situation and future perspectives
by: A. E. Russkikh, et al.
Published: (2021-01-01)

FUNCTIONAL RESPONSE TO ENDOBRONCHIAL VALVE IMPLANTING TO THOSE SUFFERING FROM PULMONARY DESTRUCTIVE TUBERCULOSIS
by: L. A. Popova, et al.
Published: (2016-09-01)

Molecular Targets Related Drug Resistance Mechanisms in MDR-, XDR-, and TDR-Mycobacterium tuberculosis Strains
by: H. M. Adnan Hameed, et al.
Published: (2018-04-01)

Impact of Whole-Genome Sequencing of <i>Mycobacterium tuberculosis</i> on Treatment Outcomes for MDR-TB/XDR-TB: A Systematic Review
by: Druti Hazra, et al.
Published: (2023-12-01)

Prevalence of pre-extensively drug-resistant tuberculosis (Pre XDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) among extra pulmonary (EP) multidrug resistant tuberculosis (MDR-TB) at a tertiary care center in Mumbai in pre Bedaquiline (BDQ) era
by: Ketaki V Utpat, et al.
Published: (2023-01-01)

The Anti-Mycobacterial Activity Of Ag, ZnO, And Ag- ZnO Nanoparticles Against MDR- And XDR-Mycobacterium tuberculosis
by: Heidary M, et al.
Published: (2019-11-01)

MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network
by: Giovanni Battista Migliori, et al.
Published: (2020-03-01)

Identification of Acinetobacter baumannii and Determination of MDR and XDR Strains
by: Noor Hussein Ahmad, et al.
Published: (2020-07-01)

THE EFFECT OF DIFFERENT TB DRUGS AND ANTIMICROBIAL AGENTS ON THE EFFICIENCY OF TREATMENT OF TUBERCULOSIS PATIENTS WITH MULTIPLE DRUG RESISTANCE
by: I. A. Vasilyeva, et al.
Published: (2017-11-01)

Global trends in the incidence rates of MDR and XDR tuberculosis: Findings from the global burden of disease study 2019
by: Qingting Bu, et al.
Published: (2023-02-01)

Changes in ventilatory and gas exchange pulmonary functions when the endobronchial valve block is effectively implanted to those with destructive pulmonary tuberculosis
by: L. A. Popova, et al.
Published: (2018-11-01)

Specific Manifestations of Neurotoxicity of Some Drug Combinations for Treatment of Drug Resistant Tuberculosis from the Perspective of Experimental Studies
by: G. N. Mozhokina, et al.
Published: (2023-01-01)

Age of Antibiotic Resistance in MDR/XDR Clinical Pathogen of <i>Pseudomonas aeruginosa</i>
by: Ashish Kothari, et al.
Published: (2023-08-01)

XDR tuberculosis: A looming threat
by: Sharma Vishal, et al.
Published: (2009-01-01)

IMPACT OF EXPRESS SUSCEPTIBILITY TESTING TO RIFAMPICIN OF M. TUBERCULOSIS ON CHEMOTHERAPY EFFICIENCY IN THOSE SUFFERING FROM MULTIPLE DRUG RESISTANT TUBERCULOSIS
by: A. G. Samoylova, et al.
Published: (2016-09-01)